COMP <GO>
ELOX vs KLRS // EV/EBITDA & P/E VALUATION
Eloxx Pharmaceuticals Inc. (NASDAQ) VS. Kalaris Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: ELOX 2
— KLRS 1
■ METRIC PARITY
LAST: $13.45 (+1.89%) • MKT CAP: $53.3M
valuation
—
LAST: $2.03 (-4.69%) • MKT CAP: $50.7M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ELOX VS. KLRS)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ELOX | KLRS | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -11.87% | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 1/9 | 3/9 | -2.00 | KLRS | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 45.4 | 41.4 | +4.03 | ELOX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $53.3M | $50.7M | $2.6M | ELOX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ELOX REV | KLRS REV | ELOX GROSS % | KLRS GROSS % | ELOX FCF | KLRS FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $0 | — | — | -$6.3M | -$38.6M |
| FY 2024 | $6.4M | $0 | — | — | -$4.7M | -$20.7M |
| FY 2023 | $0 | $0 | — | — | -$14.3M | -$124.5M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ELOX // BETA —
KLRS // BETA —